John Wilding

736 total papers · 55.1k total citations
449 papers, 35.2k citations indexed

About

John Wilding is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Physiology. According to data from OpenAlex, John Wilding has authored 449 papers receiving a total of 35.2k indexed citations (citations by other indexed papers that have themselves been cited), including 210 papers in Endocrinology, Diabetes and Metabolism, 134 papers in Molecular Biology and 121 papers in Physiology. Recurrent topics in John Wilding's work include Diabetes Treatment and Management (184 papers), Metabolism, Diabetes, and Cancer (114 papers) and Pharmacology and Obesity Treatment (86 papers). John Wilding is often cited by papers focused on Diabetes Treatment and Management (184 papers), Metabolism, Diabetes, and Cancer (114 papers) and Pharmacology and Obesity Treatment (86 papers). John Wilding collaborates with scholars based in United Kingdom, United States and Canada. John Wilding's co-authors include Ofri Mosenzon, Lawrence A. Leiter, Deepak L. Bhatt, Marc S. Sabatine, Darren K. McGuire, Avivit Cahn, Marc P. Bonaca, Thomas A. Zelniker, Eri Kato and Stephen D. Wiviott and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

John Wilding

437 papers receiving 34.1k citations

Hit Papers

Dapagliflozin and Cardiov... 1996 2026 2006 2016 2018 2021 2018 2015 1996 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    2018 4.2k citations Stephen D. Wiviott, Itamar Raz et al. New England Journal of Medicine profile →
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity
    2021 2.4k citations John Wilding, Rachel L. Batterham et al. New England Journal of Medicine profile →
  3. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
    2018 1.9k citations Thomas A. Zelniker, Stephen D. Wiviott et al. The Lancet profile →
  4. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
    2015 1.7k citations F. Xavier Pi‐Sunyer, Arne Astrup et al. New England Journal of Medicine profile →
  5. A role for glucagon-like peptide-1 in the central regulation of feeding
    1996 1.6k citations Mandy D. Turton, Donal O’Shea et al. Nature profile →
  6. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation
    2017 949 citations George A. Bray, John Wilding et al. Obesity Reviews profile →
  7. Management of obesity
    2016 720 citations George A. Bray, Gema Frühbeck et al. The Lancet profile →
  8. Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
    2012 690 citations Jan Bolinder, Östen Ljunggren et al. The Journal of Clinical Endocrinology & Metabolism profile →
  9. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs
    2017 602 citations Mikhail Kosiborod, Matthew A. Cavender et al. Circulation profile →
  10. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
    2018 566 citations Patrick M. O’Neil, Andreas L. Birkenfeld et al. The Lancet profile →
  11. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus
    2019 526 citations Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation profile →
  12. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis
    2016 501 citations Jay S. Skyler, George L. Bakris et al. Diabetes profile →
  13. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
    2022 485 citations John Wilding, Rachel L. Batterham et al. Diabetes Obesity and Metabolism profile →
  14. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
    2013 387 citations Jan Bolinder, Östen Ljunggren et al. Diabetes Obesity and Metabolism profile →
  15. Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
    2012 384 citations John Wilding et al. Annals of Internal Medicine profile →
  16. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    2021 351 citations Emily Brown, Hiddo J.L. Heerspink et al. The Lancet profile →
  17. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
    2020 307 citations Thomas A. Zelniker, Marc P. Bonaca et al. Circulation profile →
  18. Economic impacts of overweight and obesity: current and future estimates for 161 countries
    2022 268 citations Adeyemi Okunogbe, Rachel Nugent et al. BMJ Global Health profile →
  19. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
    2019 224 citations Hiddo J.L. Heerspink, Avraham Karasik et al. The Lancet Diabetes & Endocrinology profile →
  20. Economic impacts of overweight and obesity: current and future estimates for eight countries
    2021 205 citations Adeyemi Okunogbe, Rachel Nugent et al. BMJ Global Health profile →
  21. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation
    2022 169 citations Francisco López-Jiménez, Wael Almahmeed et al. European Journal of Preventive Cardiology profile →
  22. Tirzepatide for Obesity Treatment and Diabetes Prevention
    2024 117 citations Ania M. Jastreboff, Carel W. le Roux et al. New England Journal of Medicine profile →
  23. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
    2024 111 citations Donna H. Ryan, Ildiko Lingvay et al. Nature Medicine profile →
  24. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
    2024 96 citations Helen M. Colhoun, Ildiko Lingvay et al. Nature Medicine profile →
  25. New insights into the treatment of obesity
    2023 76 citations Matthias Blüher, Mohini Aras et al. Diabetes Obesity and Metabolism profile →
  26. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
    2025 26 citations W. Timothy Garvey, Matthias Blüher et al. New England Journal of Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
John Wilding 19.8k 9.4k 8.5k 8.1k 6.5k 449 35.2k
Richard E. Pratley 16.7k 0.8× 8.7k 0.9× 6.5k 0.8× 10.1k 1.2× 2.9k 0.4× 397 35.7k
William C. Knowler 22.2k 1.1× 10.5k 1.1× 8.3k 1.0× 14.4k 1.8× 3.3k 0.5× 525 57.7k
Steven E. Kahn 20.9k 1.1× 12.7k 1.3× 12.9k 1.5× 13.3k 1.6× 3.1k 0.5× 470 46.4k
Thomas A. Wadden 10.8k 0.5× 3.6k 0.4× 9.4k 1.1× 16.6k 2.0× 9.8k 1.5× 479 50.1k
James R. Sowers 14.7k 0.7× 9.9k 1.1× 6.4k 0.8× 8.7k 1.1× 3.2k 0.5× 689 42.5k
Matti Uusitupa 13.4k 0.7× 6.8k 0.7× 5.2k 0.6× 11.9k 1.5× 2.1k 0.3× 481 37.4k
Michael D. Jensen 8.1k 0.4× 5.1k 0.5× 10.5k 1.2× 19.3k 2.4× 3.0k 0.5× 323 37.6k
Dario Giugliano 13.3k 0.7× 5.8k 0.6× 4.1k 0.5× 8.7k 1.1× 2.2k 0.3× 456 32.5k
Markku Laakso 23.4k 1.2× 16.3k 1.7× 11.7k 1.4× 13.5k 1.7× 2.9k 0.4× 672 58.1k
Gerald M. Reaven 30.5k 1.5× 13.6k 1.4× 10.3k 1.2× 19.1k 2.3× 3.8k 0.6× 666 59.4k

Countries citing papers authored by John Wilding

Since Specialization
Citations

This map shows the geographic impact of John Wilding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Wilding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Wilding more than expected).

Fields of papers citing papers by John Wilding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Wilding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Wilding. The network helps show where John Wilding may publish in the future.

Co-authorship network of co-authors of John Wilding

This figure shows the co-authorship network connecting the top 25 collaborators of John Wilding. A scholar is included among the top collaborators of John Wilding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Wilding. John Wilding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas D. Anthopoulos Breakdown of academic impact, for papers by Mario Mikulincer Breakdown of academic impact, for papers by Bin Ren Breakdown of academic impact, for papers by David R. Bangsberg Breakdown of academic impact, for papers by Michael Boeckh Breakdown of academic impact, for papers by Andrzej Słomiński Breakdown of academic impact, for papers by Satoshi Minoshima Breakdown of academic impact, for papers by Siyu Lu
Rankless by CCL
2026